REGULAXIS

Their core work

REGULAXIS is a French biotech SME specializing in therapeutic solutions for cartilage degeneration, with a specific focus on gonarthrosis (knee osteoarthritis). Their work spans both medical device development — combining viscosupplementation with pharmacologically active molecules — and biotechnological drug development targeting cartilage regeneration. They successfully navigated the EU SME Instrument from Phase 1 feasibility (REGHA, 2015) through to a full Phase 2 innovation project (RHYP, 2017–2020), securing over €2.1M to bring a new biological therapy for early-stage gonarthrosis toward clinical development. Their core value is the development of proprietary therapeutic approaches that go beyond existing viscosupplementation products by combining biological and pharmacological mechanisms.

What they specialise in

How they've shifted over time

REGULAXIS began with a hybrid medical device approach — combining viscosupplementation (a well-established knee treatment) with a pharmacological molecule to enhance cartilage repair — suggesting an initial strategy of building on existing clinical pathways. By 2017, they had shifted toward a pure biotechnological therapeutic drug, indicating a move up the value chain from device-drug combination products to biologic medicines. This trajectory suggests growing regulatory and scientific confidence, moving from a lower-risk device framework toward the more ambitious but higher-value biotech drug route.

REGULAXIS is moving from combination medical devices toward standalone biologic drugs for orthopedic indications, a path that, if continued, points toward clinical trials, regulatory submission, and potential licensing or partnering with larger pharma players.

How they like to work

REGULAXIS has operated exclusively as a solo applicant under the EU SME Instrument, with no recorded consortium partners across either project. This is characteristic of companies with proprietary technology and a clear internal development roadmap — they are not consortium builders, they are IP owners seeking direct funding to advance their own pipeline. Working with REGULAXIS would likely mean engaging as a service provider, clinical partner, or licensing partner rather than as a co-equal consortium member.

REGULAXIS has no recorded consortium partners and no cross-country collaborations in their H2020 portfolio. Their projects were funded through the SME Instrument, which is designed for single-company applicants, so this absence of partners reflects funding structure rather than isolation — but it does mean their external research network is not visible through EU project data.

What sets them apart

REGULAXIS occupies a specific niche at the intersection of orthopedic medicine and biotechnology — developing therapeutic solutions for cartilage regeneration that go beyond conventional viscosupplementation products already on the market. Their demonstrated ability to advance from a Phase 1 feasibility grant to a Phase 2 innovation award (over €2M) signals that an independent evaluation panel found their science and business case credible. For a consortium looking for a specialized biotech partner in musculoskeletal disease, they bring proprietary therapeutic concepts rather than generic research capacity.

Highlights from their portfolio

• RHYP
  The largest project in their portfolio at €2.1M, representing a full Phase 2 SME Instrument award — a competitive grant awarded only to companies with credible innovation and commercial plans — for a biotechnological drug targeting early-stage knee osteoarthritis.
• REGHA
  A Phase 1 SME Instrument feasibility study that served as the validated stepping stone to RHYP, demonstrating a disciplined development progression from proof-of-concept to full innovation project within two years.